Multiplex PCR for Severe Respiratory Infections During the COVID-19 Pandemic

Viral Pneumonia Clinical Trial

— VirCoV+  

Official title:

Relevance of the Multiplex PCR Approach for Severe Respiratory Infections of Patients Hospitalized - Including an Intensive Care Unit, During the COVID-19 Pandemic

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06349707
• Other study ID #: 2023PI112
• Status: Not yet recruiting
• Start date: April 2024
• Est. completion date: June 2024

Study information

• Verified date: April 2024
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The hypothesis was that a retrospective investigation of the molecular virological tests in a University hospital could be informative, with the aim to identify non-COVID-19 respiratory viruses during the circulation of SARS-CoV-2, according to systematic population data for public health knowledge.

Description:

The hypothesis was that a retrospective investigation of the molecular virological tests in a University hospital could be informative, with the aim to identify non-COVID-19 respiratory viruses during the circulation of SARS-CoV-2, according to systematic population data for public health knowledge:

• the main goal was to perform a retrospective investigation of the molecular virological tests in a University hospital, in order to identify non-COVID-19 respiratory viruses from the beginning of 2021 to mid-2022 during the circulation of SARS-CoV-2, for public health knowledge;

• the secondary aim was to retrospectively analyze, for a small subgroup of patients from an intensive care unit, the files of patients with positive molecular virological tests for non-COVID-19 respiratory viruses from the beginning of 2021 to mid-2022, reporting the following standard-of-care data: (i) the identification of the viruses, (ii) bioclinical features, (iii) medical impact of virological results in real life.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 18
• Est. completion date: June 2024
• Est. primary completion date: May 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• For adult patients, or minors 'via' parents, able to give consent - 18 intensive care patients

Exclusion Criteria:

• Non-inclusion in case of refusal

Related Conditions & MeSH terms

• COVID-19
• Pneumonia, Viral
• Respiratory Tract Infections
• Viral Pneumonia

Intervention

Other:
• other: Observational
For 18 ICU patients, retrospective collection of routine bioclinical database (ICCA db)

Locations

Country	Name	City	State
France	Schvoerer	Vandoeuvre Les Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of positive viral PCR assays (not COVID-19) from hospitalizations for respiratory infections.	Number of patients with positive virological molecular tests (multiplex respiratory panels) from the beginning of 2021 to mid-2022, with the nature of the viruses detected and the chronology of occurrence of positive tests.	18 months, retrospectively
Secondary	Real-life features of patients in Intensive care (from the whole population - Outcome 1) with positive viral PCR during infectious pneumonia.	For the group of patients in Intensive Care: (i) number of positive molecular virological tests detecting respiratory viruses by FilmArray Pneumonia test; (ii) associated bioclinical data; (iii) medical impact of virological results in real life - progression of the infection and duration of thehospitalization.	18 months, retrospectively